vs

Side-by-side financial comparison of RAPID MICRO BIOSYSTEMS, INC. (RPID) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.

SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $11.3M, roughly 1.1× RAPID MICRO BIOSYSTEMS, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -110.8%, a 112.1% gap on every dollar of revenue. On growth, RAPID MICRO BIOSYSTEMS, INC. posted the faster year-over-year revenue change (37.3% vs -0.7%). Over the past eight quarters, RAPID MICRO BIOSYSTEMS, INC.'s revenue compounded faster (41.8% CAGR vs 12.5%).

Rapid Micro Biosystems, Inc. develops and manufactures automated microbial detection and quality control solutions for the life sciences industry. Its core products serve biopharmaceutical manufacturers, contract development and manufacturing organizations, operating across key global markets including North America, Europe and Asia-Pacific, helping clients cut testing timelines and improve operational efficiency.

RPID vs SLSN — Head-to-Head

Bigger by revenue
SLSN
SLSN
1.1× larger
SLSN
$12.5M
$11.3M
RPID
Growing faster (revenue YoY)
RPID
RPID
+38.0% gap
RPID
37.3%
-0.7%
SLSN
Higher net margin
SLSN
SLSN
112.1% more per $
SLSN
1.3%
-110.8%
RPID
Faster 2-yr revenue CAGR
RPID
RPID
Annualised
RPID
41.8%
12.5%
SLSN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RPID
RPID
SLSN
SLSN
Revenue
$11.3M
$12.5M
Net Profit
$-12.5M
$163.0K
Gross Margin
27.5%
Operating Margin
-108.2%
1.5%
Net Margin
-110.8%
1.3%
Revenue YoY
37.3%
-0.7%
Net Profit YoY
-29.3%
129.2%
EPS (diluted)
$-0.26
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPID
RPID
SLSN
SLSN
Q4 25
$11.3M
$12.5M
Q3 25
$7.8M
$14.6M
Q2 25
$7.3M
$20.4M
Q1 25
$7.2M
$14.6M
Q4 24
$8.2M
$12.6M
Q3 24
$7.6M
$16.9M
Q2 24
$6.6M
$13.0M
Q1 24
$5.6M
$9.9M
Net Profit
RPID
RPID
SLSN
SLSN
Q4 25
$-12.5M
$163.0K
Q3 25
$-11.5M
$-1.1M
Q2 25
$-11.9M
$2.7M
Q1 25
$-11.3M
$80.0K
Q4 24
$-9.7M
$-559.0K
Q3 24
$-11.3M
$3.0M
Q2 24
$-12.6M
$856.0K
Q1 24
$-13.3M
$893.0K
Gross Margin
RPID
RPID
SLSN
SLSN
Q4 25
27.5%
Q3 25
23.1%
Q2 25
28.9%
Q1 25
23.1%
Q4 24
22.0%
Q3 24
36.2%
Q2 24
28.7%
Q1 24
36.3%
Operating Margin
RPID
RPID
SLSN
SLSN
Q4 25
-108.2%
1.5%
Q3 25
-145.1%
-5.4%
Q2 25
-167.3%
9.4%
Q1 25
-161.8%
1.8%
Q4 24
-124.5%
-1.8%
Q3 24
-158.3%
19.0%
Q2 24
-202.1%
8.0%
Q1 24
-254.4%
11.3%
Net Margin
RPID
RPID
SLSN
SLSN
Q4 25
-110.8%
1.3%
Q3 25
-146.8%
-7.7%
Q2 25
-163.3%
13.1%
Q1 25
-156.3%
0.5%
Q4 24
-117.6%
-4.4%
Q3 24
-148.9%
18.1%
Q2 24
-190.1%
6.6%
Q1 24
-237.4%
9.0%
EPS (diluted)
RPID
RPID
SLSN
SLSN
Q4 25
$-0.26
$0.00
Q3 25
$-0.26
$-0.02
Q2 25
$-0.27
$0.04
Q1 25
$-0.26
$0.00
Q4 24
$-0.22
$0.00
Q3 24
$-0.26
$0.04
Q2 24
$-0.29
$0.01
Q1 24
$-0.31
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPID
RPID
SLSN
SLSN
Cash + ST InvestmentsLiquidity on hand
$20.0M
$1.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$33.2M
$17.6M
Total Assets
$74.9M
$50.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPID
RPID
SLSN
SLSN
Q4 25
$20.0M
$1.3M
Q3 25
$18.9M
$429.0K
Q2 25
$18.3M
$4.1M
Q1 25
$18.9M
$1.8M
Q4 24
$16.9M
$1.4M
Q3 24
$22.0M
$2.9M
Q2 24
$37.1M
$2.4M
Q1 24
$22.4M
$2.0M
Stockholders' Equity
RPID
RPID
SLSN
SLSN
Q4 25
$33.2M
$17.6M
Q3 25
$44.3M
$17.2M
Q2 25
$54.5M
$18.2M
Q1 25
$65.5M
$15.2M
Q4 24
$75.4M
$14.9M
Q3 24
$84.4M
$15.2M
Q2 24
$94.6M
$11.9M
Q1 24
$105.9M
$5.0M
Total Assets
RPID
RPID
SLSN
SLSN
Q4 25
$74.9M
$50.1M
Q3 25
$84.4M
$54.0M
Q2 25
$75.6M
$60.0M
Q1 25
$85.4M
$57.0M
Q4 24
$98.2M
$50.0M
Q3 24
$105.8M
$48.0M
Q2 24
$117.1M
$40.8M
Q1 24
$127.7M
$38.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPID
RPID
SLSN
SLSN
Operating Cash FlowLast quarter
$-3.2M
$1.8M
Free Cash FlowOCF − Capex
$-3.3M
FCF MarginFCF / Revenue
-29.6%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
11.16×
TTM Free Cash FlowTrailing 4 quarters
$-31.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPID
RPID
SLSN
SLSN
Q4 25
$-3.2M
$1.8M
Q3 25
$-9.1M
$-2.5M
Q2 25
$-9.7M
$-654.0K
Q1 25
$-9.1M
$-7.2M
Q4 24
$-9.9M
$2.2M
Q3 24
$-8.6M
$4.2M
Q2 24
$-10.1M
$-565.0K
Q1 24
$-15.5M
$-3.9M
Free Cash Flow
RPID
RPID
SLSN
SLSN
Q4 25
$-3.3M
Q3 25
$-9.1M
Q2 25
$-10.1M
Q1 25
$-9.4M
Q4 24
$-10.0M
$-404.0K
Q3 24
$-8.8M
$2.8M
Q2 24
$-10.6M
$-1.0M
Q1 24
$-16.1M
$-3.9M
FCF Margin
RPID
RPID
SLSN
SLSN
Q4 25
-29.6%
Q3 25
-116.4%
Q2 25
-138.6%
Q1 25
-130.2%
Q4 24
-121.8%
-3.2%
Q3 24
-116.0%
16.6%
Q2 24
-159.8%
-8.0%
Q1 24
-287.1%
-39.9%
Capex Intensity
RPID
RPID
SLSN
SLSN
Q4 25
0.8%
Q3 25
0.9%
Q2 25
5.0%
Q1 25
4.4%
Q4 24
1.2%
20.6%
Q3 24
2.9%
8.3%
Q2 24
6.9%
3.7%
Q1 24
10.4%
0.9%
Cash Conversion
RPID
RPID
SLSN
SLSN
Q4 25
11.16×
Q3 25
Q2 25
-0.25×
Q1 25
-90.26×
Q4 24
Q3 24
1.38×
Q2 24
-0.66×
Q1 24
-4.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPID
RPID

Products$9.3M83%
Services$2.0M17%

SLSN
SLSN

Segment breakdown not available.

Related Comparisons